News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024

Harrow Health, Inc. (NASDAQ: HROW) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $24.00 price target on the stock.

Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing

Harrow Health, Inc. (NASDAQ: HROW) had its price target lowered by analysts at B. Riley from $30.00 to $26.00. They now have a "buy" rating on the stock.

Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript [Yahoo! Finance]

11/13/2023

04:01 pm

HROW

-36.0%

MISS

8/9/2023

04:01 pm

HROW

-15.5%

MISS

5/11/2023

04:01 pm

HROW

-18.6%

BEAT

Form DEFA14A HARROW, INC.

Form DEF 14A HARROW, INC. For: Apr 26

Form 4 HARROW, INC. For: Apr 25 Filed by: Opaleye Management Inc.

Form 4 HARROW, INC. For: Apr 23 Filed by: Opaleye Management Inc.

Form 4 HARROW, INC. For: Apr 19 Filed by: Opaleye Management Inc.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}